Restricted accessResearch articleFirst published online 2025-10
Diagnosis and management of cerebral amyloid angiopathy: a scientific statement from the International CAA Association and the World Stroke Organization
Cerebral amyloid angiopathy (CAA) is a well-recognized and challenging disease for neurologists and other clinicians caring for the rapidly aging worldwide population. CAA is a major cause of spontaneous lobar intracerebral hemorrhage (ICH), and can also cause transient focal neurological episodes, and convexity subarachnoid hemorrhage, CAA-associated ICH has a high mortality, morbidity, and recurrence rate. CAA can affect a wide range of clinical decisions including use of antithrombotic medications, safety for anti-β-amyloid peptide (Aβ) immunotherapy, and need for anti-inflammatory or immunosuppressive treatment. We present guidelines, intended to inform the approach to individuals with suspected CAA, written on behalf of the International CAA Association and the World Stroke Organization (WSO). We cover five areas selected for their relevance to practice: (1) diagnosis, testing, and prediction of intracerebral hemorrhage risk; (2) antithrombotic agents and vascular interventions; (3) vascular risk factors and concomitant medications; (4) treatment of CAA manifestations; and (5) diagnosis and treatment of CAA-related inflammation and vasculitis. The statement has been reviewed and approved by the Executive Committee of the WSO, and the International CAA Association.
BanerjeeGCollingeJFoxNC, et al. Clinical considerations in early-onset cerebral amyloid angiopathy. Brain2023; 146: 3991–4014.
2.
CharidimouABoulouisGFroschMP, et al. The Boston criteria version 2.0 for cerebral amyloid angiopathy: a multicentre, retrospective, MRI-neuropathology diagnostic accuracy study. Lancet Neurol2022; 21: 714–725.
3.
RodriguesMASamarasekeraNLerpiniereC, et al. The Edinburgh CT and genetic diagnostic criteria for lobar intracerebral haemorrhage associated with cerebral amyloid angiopathy: model development and diagnostic test accuracy study. Lancet Neurol2018; 17: 232–240.
4.
BoylePAYuLWilsonRSLeurgansSESchneiderJABennettDA.Person-specific contribution of neuropathologies to cognitive loss in old age. Ann Neurol2018; 83: 74–83.
5.
KoemansEAChhatwalJPvan VeluwSJ, et al. Progression of cerebral amyloid angiopathy: a pathophysiological framework. Lancet Neurol2023; 22: 632–642.
CharidimouA.Cerebral amyloid angiopathy-related inflammation spectrum disorders: introduction of a novel concept and diagnostic criteria. Ann Neurol2025; 97: 470–474.
8.
CharidimouAFroschMPAl-Shahi SalmanR, et al. Advancing diagnostic criteria for sporadic cerebral amyloid angiopathy: Study protocol for a multicenter MRI-pathology validation of Boston criteria v2.0.International journal of stroke: official journal of the International Stroke Society. 2019;14:956–971. DOI: 10.1177/1747493019855888
9.
BanerjeeGSamraKAdamsME, et al. Iatrogenic cerebral amyloid angiopathy: an emerging clinical phenomenon. J Neurol Neurosurg Psychiatry2022; 93: 693–700.
10.
DueringMBiesselsGJBrodtmannA, et al. Neuroimaging standards for research into small vessel disease-advances since 2013. Lancet Neurol2023; 22: 602–618.
11.
NandigamRNViswanathanADelgadoP, et al. MR imaging detection of cerebral microbleeds: effect of susceptibility-weighted imaging, section thickness, and field strength. AJNR Am J Neuroradiol2009; 30: 338–343.
12.
Zanon ZotinMCMakkinejadNSchneiderJA, et al. Sensitivity and specificity of the Boston criteria v2.0 for the diagnosis of cerebral amyloid angiopathy in a community-based sample. Neurology2024; 102: e207940.
13.
SwitzerARCharidimouAMcCarterS, et al. Boston criteria v2.0 for cerebral amyloid angiopathy without hemorrhage: an MRI-neuropathologic validation study. Neurology2024; 102: e209386.
14.
DasASGokcalEBiffiA, et al. Mechanistic implications of cortical superficial siderosis in patients with mixed location intracerebral hemorrhage and cerebral microbleeds. Neurology2023; 101: e636–e644.
15.
SembillJAKnottMXuM, et al. Simplified Edinburgh ct criteria for identification of lobar intracerebral hemorrhage associated with cerebral amyloid angiopathy. Neurology2022; 98: e1997–e2004.
16.
van EttenESKaushikKvan ZwetEW, et al. Sensitivity of the Edinburgh criteria for lobar intracerebral hemorrhage in hereditary cerebral amyloid angiopathy. Stroke2020; 51: 3608–3612.
17.
CharidimouAFriedrichJOGreenbergSMViswanathanA.Core cerebrospinal fluid biomarker profile in cerebral amyloid angiopathy: a meta-analysis. Neurology2018; 90: e754–e762.
18.
MargrafNGJensen-KonderingUWeilerC, et al. Cerebrospinal fluid biomarkers in cerebral amyloid angiopathy: new data and quantitative meta-analysis. Front Aging Neurosci2022; 14: 783996.
19.
FaridKCharidimouABaronJC.Amyloid positron emission tomography in sporadic cerebral amyloid angiopathy: a systematic critical update. Neuroimage Clin2017; 15: 247–263.
20.
CharidimouAFaridKTsaiHHTsaiLKYenRFBaronJC.Amyloid-PET burden and regional distribution in cerebral amyloid angiopathy: a systematic review and meta-analysis of biomarker performance. J Neurol Neurosurg Psychiatry2018; 89: 410–417.
21.
MuirRTIsmailZBlackSESmithEE.Comparative methods for quantifying plasma biomarkers in Alzheimer’s disease: implications for the next frontier in cerebral amyloid angiopathy diagnostics. Alzheimers Dement2024; 20: 1436–1458.
22.
GreenbergSMZiaiWCCordonnierC, et al. 2022 guideline for the management of patients with spontaneous intracerebral hemorrhage: a guideline from the American Heart Association/American Stroke Association. Stroke2022; 53: e282–e361.
23.
SteinerTAl-Shahi SalmanRBeerR, et al. European Stroke Organisation (ESO) guidelines for the management of spontaneous intracerebral hemorrhage. Int J Stroke2014; 9: 840–855.
24.
ShoamaneshAPatrice LindsayMCastellucciLA, et al. Canadian stroke best practice recommendations: management of spontaneous intracerebral hemorrhage. Int J Stroke2021; 16: 321–341.
25.
CharidimouAImaizumiTMoulinS, et al. Brain hemorrhage recurrence, small vessel disease type, and cerebral microbleeds: a meta-analysis. Neurology2017; 89: 820–829.
26.
HostettlerICWilsonDFiebelkornCA, et al. Risk of intracranial haemorrhage and ischaemic stroke after convexity subarachnoid haemorrhage in cerebral amyloid angiopathy: international individual patient data pooled analysis. J Neurol2022; 269: 1427–1438.
27.
CharidimouABoulouisGGreenbergSMViswanathanA.Cortical superficial siderosis and bleeding risk in cerebral amyloid angiopathy: a meta-analysis. Neurology2019; 93: e2192–e202.
28.
CharidimouABoulouisGRoongpiboonsopitD, et al. Cortical superficial siderosis and recurrent intracerebral hemorrhage risk in cerebral amyloid angiopathy: large prospective cohort and preliminary meta-analysis. Int J Stroke2019; 14: 723–733.
29.
Antithrombotic TrialistsCBaigentCBlackwellL, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet2009; 373: 1849–1860.
30.
WilsonDAmblerGLeeKJ, et al. Cerebral microbleeds and stroke risk after ischaemic stroke or transient ischaemic attack: a pooled analysis of individual patient data from cohort studies. Lancet Neurol2019; 18: 653–665.
31.
O’DonnellMJEikelboomJWYusufS, et al. Effect of apixaban on brain infarction and microbleeds: AVERROES-MRI assessment study. Am Heart J2016; 178: 145–150.
32.
Al-Shahi SalmanRDennisMSSandercockPAG, et al. Effects of antiplatelet therapy after stroke caused by intracerebral hemorrhage: extended follow-up of the RESTART randomized clinical trial. JAMA Neurol2021; 78: 1179–1186.
33.
RestartCollaboration. Effects of antiplatelet therapy after stroke due to intracerebral haemorrhage (RESTART): a randomised, open-label trial. Lancet2019; 393: 2613–2623.
34.
Al-Shahi SalmanRMinksDPMitraD, et al. Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART randomised, open-label trial. Lancet Neurol2019; 18: 643–652.
35.
SchreuderFHBMvan NieuwenhuizenKMHofmeijerJ, et al. Apixaban versus no anticoagulation after anticoagulation-associated intracerebral haemorrhage in patients with atrial fibrillation in the Netherlands (APACHE-AF): a randomised, open-label, phase 2 trial. Lancet Neurol2021; 20: 907–916.
36.
SoSTART Collaboration. Effects of oral anticoagulation for atrial fibrillation after spontaneous intracranial haemorrhage in the UK: a randomised, open-label, assessor-masked, pilot-phase, non-inferiority trial. Lancet Neurol2021; 20: 842–853.
37.
ConnollySJEikelboomJJoynerC, et al. Apixaban in patients with atrial fibrillation. N Engl J Med2011; 364: 806–817.
38.
GrangerCBAlexanderJHMcMurrayJJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med2011; 365: 981–992.
39.
GiuglianoRPRuffCTBraunwaldE, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med2013; 369: 2093–2104.
40.
ConnollySJEzekowitzMDYusufS, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med2009; 361: 1139–1151.
41.
PatelMRMahaffeyKWGargJ, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med2011; 365: 883–891.
42.
VeltkampRKorompokiEHarveyKH, et al. Direct oral anticoagulants versus no anticoagulation for the prevention of stroke in survivors of intracerebral haemorrhage with atrial fibrillation (PRESTIGE-AF): a multicentre, open-label, randomised, phase 3 trial. Lancet2025; 405: 927–936.
43.
OkumuraKAkaoMYoshidaT, et al. Low-dose edoxaban in very elderly patients with atrial fibrillation. N Engl J Med2020; 383: 1735–1745.
44.
Al-Shahi SalmanRStephenJTierneyJF, et al. Effects of oral anticoagulation in people with atrial fibrillation after spontaneous intracranial haemorrhage (COCROACH): prospective, individual participant data meta-analysis of randomised trials. Lancet Neurol2023; 22: 1140–1149.
45.
ShoamaneshA and ENRICH-Af Steering Committee. Anticoagulation in patients with cerebral amyloid angiopathy. Lancet2023; 402: 1418–1419.
46.
SarafKMorrisGM.Left atrial appendage closure: what the evidence does and does not reveal-a view from the outside. Card Electrophysiol Clin2023; 15: 169–181.
47.
ThiankhawKBestJSrivastavaS, et al. Left atrial appendage occlusion in patients with atrial fibrillation and intracerebral haemorrhage associated with cerebral amyloid angiopathy: a multicentre observational study and pooled analysis of published studies. J Neurol Neurosurg Psychiatry2024; 96: 528–536.
48.
LabafASvenssonPJRenlundHJeppssonASjälanderA.Incidence and risk factors for thromboembolism and major bleeding in patients with mechanical valve prosthesis: a nationwide population-based study. Am Heart J2016; 181: 1–9.
49.
DerrazICagnazzoFGaillardN, et al. Microbleeds, cerebral hemorrhage, and functional outcome after endovascular thrombectomy. Neurology2021; 96: e1724–e1731.
50.
CharidimouATurcGOppenheimC, et al. Microbleeds, cerebral hemorrhage, and functional outcome after stroke thrombolysis. Stroke2017; 48: 2084–2090.
51.
SchlemmLBraemswigTBBoutitieF, et al. Cerebral microbleeds and treatment effect of intravenous thrombolysis in acute stroke: an analysis of the WAKE-UP randomized clinical trial. Neurology2022; 98: e302–e314.
52.
WagnerAMadererJWilflingS, et al. Cerebrovascular risk factors in possible or probable cerebral amyloid angiopathy, modifier or bystander?Front Neurol2021; 12: 676931.
53.
O’DonnellMJXavierDLiuL, et al. Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study. Lancet2010; 376: 112–123.
54.
BetriseySHallerMLEfthimiouO, et al. Lipid-lowering therapy and risk of hemorrhagic stroke: a systematic review and meta-analysis of randomized controlled trials. J Am Heart Assoc2024; 13: e030714.
55.
Sanz-CuestaBESaverJL.lipid-lowering therapy and hemorrhagic stroke risk: comparative meta-analysis of statins and PCSK9 inhibitors. Stroke2021; 52: 3142–3150.
56.
PezziniAGrassiMIacovielloL, et al. Serum cholesterol levels, HMG-CoA reductase inhibitors and the risk of intracerebral haemorrhage. The Multicenter Study on Cerebral Haemorrhage in Italy (MUCH-Italy). J Neurol Neurosurg Psychiatry2016; 87: 924–929.
57.
TeohRJJHuangCJChanCP, et al. Does statin increase the risk of intracerebral hemorrhage in stroke survivors? A meta-analysis and trial sequential analysis. Ther Adv Neurol Disord2019; 12: 1756286419864830.
58.
KubiszewskiPSugitaLKourkoulisC, et al. Association of selective serotonin reuptake inhibitor use after intracerebral hemorrhage with hemorrhage recurrence and depression severity. JAMA Neurol2020; 78: 1–8.
59.
HackamDGMrkobradaM.Selective serotonin reuptake inhibitors and brain hemorrhage: a meta-analysis. Neurology2012; 79: 1862–1865.
60.
IslamMMPolyTNWaltherBAYangHCLinMCLiYC.Risk of hemorrhagic stroke in patients exposed to nonsteroidal anti-inflammatory drugs: a meta-analysis of observational studies. Neuroepidemiology2018; 51: 166–176.
61.
UngprasertPMattesonELThongprayoonC.Nonaspirin nonsteroidal anti-inflammatory drugs and risk of hemorrhagic stroke: a systematic review and meta-analysis of observational studies. Stroke2016; 47: 356–364.
62.
VoigtSRasingIvan der PlasMC, et al. The impact of vascular risk factors on cerebral amyloid angiopathy: a cohort study in hereditary cerebral amyloid angiopathy and a systemic review in sporadic cerebral amyloid angiopathy. Cerebrovasc Dis. Epub ahead of print 18 November 2024. DOI: 10.1159/000542666.
63.
ZahuranecDBWingJJEdwardsDF, et al. Poor long-term blood pressure control after intracerebral hemorrhage. Stroke2012; 43: 2580–2585.
64.
BiffiAAndersonCDBatteyTW, et al. Association between blood pressure control and risk of recurrent intracerebral hemorrhage. JAMA2015; 314: 904–912.
65.
PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet2001; 358: 1033–1041.
66.
ChapmanNHuxleyRAndersonC, et al. Effects of a perindopril-based blood pressure-lowering regimen on the risk of recurrent stroke according to stroke subtype and medical history: the PROGRESS Trial. Stroke2004; 35: 116–121.
67.
ArimaHTzourioCAndersonC, et al. Effects of perindopril-based lowering of blood pressure on intracerebral hemorrhage related to amyloid angiopathy: the PROGRESS trial. Stroke2010; 41: 394–396.
68.
HilkensNAGrevingJPAlgraAKlijnCJ.Blood pressure levels and the risk of intracerebral hemorrhage after ischemic stroke. Neurology2017; 88: 177–181.
69.
BenaventeORCoffeyCSConwitR, et al. Blood-pressure targets in patients with recent lacunar stroke: the SPS3 randomised trial. Lancet2013; 382: 507–515.
70.
Pontes-NetoOMFernandesRMSanderHH, et al. Obstructive sleep apnea is frequent in patients with hypertensive intracerebral hemorrhage and is related to perihematoma edema. Cerebrovasc Dis2010; 29: 36–42.
71.
GoldsteinLBTothPPDearborn-TomazosJL, et al. Aggressive LDL-C lowering and the brain: impact on risk for dementia and hemorrhagic stroke: a scientific statement from the American Heart Association. Arterioscler Thromb Vasc Biol2023; 43: e404–e442.
72.
ShoamaneshASelimM.Use of lipid-lowering drugs after intracerebral hemorrhage. Stroke2022; 53: 2161–2170.
73.
HaussenDCHenningerNKumarSSelimM.Statin use and microbleeds in patients with spontaneous intracerebral hemorrhage. Stroke2012; 43: 2677–2681.
74.
WooDDekaRFalconeGJ, et al. Apolipoprotein E, statins, and risk of intracerebral hemorrhage. Stroke2013; 44: 3013–3017.
75.
GaistDGarcia RodriguezLAHallasJ, et al. Association of statin use with risk of stroke recurrence after intracerebral hemorrhage. Neurology2023; 101: e1793–e1806.
76.
ZiffOJBanerjeeGAmblerGWerringDJ.Statins and the risk of intracerebral haemorrhage in patients with stroke: systematic review and meta-analysis. J Neurol Neurosurg Psychiatry2019; 90: 75–83.
77.
WinklerJShoupJPCzapA, et al. Long-term improvement in outcome after intracerebral hemorrhage in patients treated with statins. J Stroke Cerebrovasc Dis2013; 22: e541–545.
78.
DowlatshahiDDemchukAMFangJ, et al. Association of statins and statin discontinuation with poor outcome and survival after intracerebral hemorrhage. Stroke2012; 43: 1518–1523.
79.
JensenMPZiffOJBanerjeeGAmblerGWerringDJ.The impact of selective serotonin reuptake inhibitors on the risk of intracranial haemorrhage: a systematic review and meta-analysis. Eur Stroke J2019; 4: 144–152.
80.
BattleCEAbdul-RahimAHShenkinSDHewittJQuinnTJ.Cholinesterase inhibitors for vascular dementia and other vascular cognitive impairments: a network meta-analysis. Cochrane Database Syst Rev2021; 2: CD013306.
81.
CharidimouABaronJCWerringDJ.Transient focal neurological episodes, cerebral amyloid angiopathy, and intracerebral hemorrhage risk: looking beyond TIAs. Int J Stroke2013; 8: 105–108.
82.
StantonJEDChandrathevaAWilsonDHostettlerICIslamSWerringDJ.Clinical features distinguish cerebral amyloid angiopathy-associated convexity subarachnoid haemorrhage from suspected TIA. J Neurol2020; 267: 133–137.
83.
CharidimouAPeetersAFoxZ, et al. Spectrum of transient focal neurological episodes in cerebral amyloid angiopathy: multicentre magnetic resonance imaging cohort study and meta-analysis. Stroke2012; 43: 2324–2330.
84.
CharidimouABoulouisGXiongL, et al. Cortical superficial siderosis and first-ever cerebral hemorrhage in cerebral amyloid angiopathy. Neurology2017; 88: 1607–1614.
85.
FilippiMCecchettiGSpinelliEGVezzulliPFaliniAAgostaF.Amyloid-related imaging abnormalities and beta-amyloid-targeting antibodies: a systematic review. JAMA Neurology2022; 79: 291–304.
GreenbergSMAparicioHJFurieKL, et al. Vascular neurology considerations for antiamyloid immunotherapy: a science advisory from the American Heart Association. Stroke2025; 56: e30–e38.
88.
ZimmerJAArdayfioPWangH, et al. Amyloid-related imaging abnormalities with donanemab in early symptomatic Alzheimer disease: secondary analysis of the TRAILBLAZER-ALZ and ALZ 2 randomized clinical Trials. JAMA Neurology2025; 82: 461–469.
89.
GreenbergSMCordonnierCSchneiderJA, et al. Off-label use of aducanumab for cerebral amyloid angiopathy. Lancet Neurol2021; 20: 596–597.
90.
CummingsJApostolovaLRabinoviciGD, et al. Lecanemab: appropriate use recommendations. J Prev Alzheimers Dis2023; 10: 362–377.
91.
RabinoviciGDSelkoeDJSchindlerSE, et al. Donanemab: appropriate use recommendations. J Prev Alzheimers Dis2025; 12: 100150.
92.
ShoamaneshAPatrice LindsayMCastellucciLA, et al. Canadian stroke best practice recommendations: management of spontaneous intracerebral hemorrhage, 7th edition update 2020. Int J Stroke2021; 16: 321–341.
93.
PradillaGRatcliffJJHallAJ, et al. Trial of early minimally invasive removal of intracerebral hemorrhage. N Engl J Med2024; 390: 1277–1289.
94.
de BruinOFVoigtSSchoonesJWMoojenWAvan EttenESWermerMJH.Surgical intervention for cerebral amyloid angiopathy-related lobar intracerebral hemorrhage: a systematic review. J Neurosurg2024; 141: 955–965.
95.
GreenbergSMVonsattelJP.Diagnosis of cerebral amyloid angiopathy. Sensitivity and specificity of cortical biopsy. Stroke1997; 28: 1418–1422.
96.
EngJAFroschMPChoiKRebeckGWGreenbergSM.Clinical manifestations of cerebral amyloid angiopathy-related inflammation. Ann Neurol2004; 55: 250–256.
97.
MurphyMNSimaAA.Cerebral amyloid angiopathy associated with giant cell arteritis: a case report. Stroke1985; 16: 514–517.
98.
KinnecomCLevMHWendellL, et al. Course of cerebral amyloid angiopathy-related inflammation. Neurology2007; 68: 1411–1416.
99.
ChungKKAndersonNEHutchinsonDSynekBBarberPA.Cerebral amyloid angiopathy related inflammation: three case reports and a review. J Neurol Neurosurg Psychiatry2011; 82: 20–26.
100.
RegenhardtRWThonJMDasAS, et al. Association between immunosuppressive treatment and outcomes of cerebral amyloid angiopathy-related inflammation. JAMA Neurol2020; 77: 1261–1269.
101.
AntoliniLDiFrancescoJCZeddeM, et al. Spontaneous ARIA-like events in cerebral amyloid angiopathy-related inflammation: a multicenter prospective longitudinal cohort study. Neurology2021; 97: e1809–e1822.
102.
AghettiASèneDPolivkaM, et al. Cerebral amyloid angiopathy related inflammation with prominent meningeal involvement. A report of 2 cases. Front Neurol2019; 10: 984.
103.
CharidimouAFaridKBaronJC.Amyloid-PET in sporadic cerebral amyloid angiopathy: a diagnostic accuracy meta-analysis. Neurology2017; 89: 1490–1498.
104.
WerringDJSperlingR.Inflammatory cerebral amyloid angiopathy and amyloid-modifying therapies: variations on the same ARIA. Ann Neurol2013; 73: 439–441.
ScoldingNJJosephFKirbyPA, et al. Abeta-related angiitis: primary angiitis of the central nervous system associated with cerebral amyloid angiopathy. Brain2005; 128: 500–515.
107.
AurielECharidimouAGurolME, et al. Validation of clinicoradiological criteria for the diagnosis of cerebral amyloid angiopathy-related inflammation. JAMA Neurol2016; 73: 197–202.
108.
TheodorouAPalaiodimouLMalhotraK, et al. Clinical, neuroimaging, and genetic markers in cerebral amyloid angiopathy-related inflammation: a systematic review and meta-analysis. Stroke2023; 54: 178–188.
109.
PiazzaFGreenbergSMSavoiardoM, et al. Anti-amyloid beta autoantibodies in cerebral amyloid angiopathy-related inflammation: implications for amyloid-modifying therapies. Ann Neurol2013; 73: 449–458.
110.
KimuraASakuraiTYoshikuraN, et al. Corticosteroid therapy in a patient with cerebral amyloid angiopathy-related inflammation. J Neuroinflammation2013; 10: 39.
111.
KimuraATakemuraMSaitoKYoshikuraNHayashiYInuzukaT.Association between naturally occurring anti-amyloid beta autoantibodies and medial temporal lobe atrophy in Alzheimer’s disease. J Neurol Neurosurg Psychiatry2017; 88: 126–131.
112.
Carmona-IraguiMFernandez-ArcosAAlcoleaD, et al. Cerebrospinal fluid anti-amyloid-beta autoantibodies and amyloid PET in cerebral amyloid angiopathy-related inflammation. J Alzheimers Dis2016; 50: 1–7.
113.
PoliLDe GiuliVPiazzaF, et al. A challenging diagnosis of reversible “vascular” dementia: cerebral amyloid angiopathy-related inflammation. J Neuroimmunol2020; 338: 577109.
114.
SakaiKNoguchi-ShinoharaMTanakaH, et al. Cerebrospinal fluid biomarkers and amyloid-beta elimination from the brain in cerebral amyloid angiopathy-related inflammation. J Alzheimers Dis2023; 91: 1173–1183.
115.
van den BergERoelofsRJakelL, et al. No replicating evidence for anti-amyloid-beta autoantibodies in cerebral amyloid angiopathy-related inflammation. Ann Clin Transl Neurol2024; 11: 2563–2571.
116.
CharidimouA. Cerebral amyloid angiopathy-related inflammation biomarkers: where are we now?J Alzheimers Dis2015; 50: 9–11.
117.
FountainNBLopesMB.Control of primary angiitis of the CNS associated with cerebral amyloid angiopathy by cyclophosphamide alone. Neurology1999; 52: 660–662.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
